CIC
RYTM icon

Cornercap Investment Counsel’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cornercap Investment Counsel’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,663
Closed -$152K – 618
2022
Q2 		$152K Buy
+36,663
New +$201K 0.03% 503

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cornercap Investment Counsel's RYTM Position: Q3 2022 in Review

Cornercap Investment Counsel sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2022, closing a stake of 36,663 shares — an estimated $152K sold.

Cornercap Investment Counsel first reported a position in RYTM in Q2 2022 and held it in 1 quarter. The position peaked at $152K in Q2 2022. 101 funds tracked by Wall St. Rank hold RYTM as of Q3 2022.

  • Cornercap Investment Counsel reported no remaining Rhythm Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 36,663 Rhythm Pharmaceuticals shares in Q3 2022, an estimated $152K.
  • Cornercap Investment Counsel first reported a position in Rhythm Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Cornercap Investment Counsel's Rhythm Pharmaceuticals position peaked at $152K in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2022.

Based on Cornercap Investment Counsel's 13F filing for Q3 2022, filed 14 Nov 2022.